SAN DIEGO--(BUSINESS WIRE)-- Santarus, Inc. (NASDAQ:SNTS) announces the following webcast:

What: Lippert/Heilshorn Life Sciences Virtual Conference

Date: Tuesday, December 15, 2009

Time: 10:30 a.m. Eastern time (7:30 a.m. Pacific time)

Speaker: Gerald T. Proehl, Santarus president and chief executive officer

The webcast can be accessed by visiting the Investor Relations section of the company’s Web site at www.santarus.com. The webcast presentation will be archived and available on the Web site for 14 days.

About Santarus

Santarus, Inc. is a specialty biopharmaceutical company focused on acquiring, developing and commercializing proprietary products that address the needs of patients treated by gastroenterologists and other physicians. The company’s current commercial efforts are focused on ZEGERID^® (omeprazole/sodium bicarbonate), which is indicated for the treatment of certain upper GI diseases and disorders, and on GLUMETZA^® (metformin hydrochloride extended release tablets), which is indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes. Santarus is also developing two late-stage lower GI product candidates, budesonide MMX^® and rifamycin SV MMX^®, for the U.S. market. Budesonide MMX is being investigated in two multicenter Phase III clinical trials for the induction of remission of mild or moderate active ulcerative colitis. Rifamycin SV MMX has been investigated in a Phase II clinical program in travelers’ diarrhea. More information about Santarus is available on the company’s Web site at www.santarus.com.

Santarus^® and ZEGERID^® are registered trademarks of Santarus, Inc. GLUMETZA^® is a registered trademark of Biovail Laboratories International S.r.l. licensed exclusively in the United States to Depomed, Inc. MMX^® is a registered trademark of Cosmo Technologies Limited.

Santarus, Inc.
Martha Hough
VP Finance & Investor Relations
858-314-5824

Source: Santarus, Inc.